MDT Medtronic plc
XNYS
100.39
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
What changed
Recent filings, trades and moves- 52-Week Range
- $73.31 – $106.33
- YTD
- +4.52%
- IV Rank (30D)
- 65.89
- Straddle Price
- $6.87
- P/C Vol Ratio
- 1.36
- Market Cap
- $128.8B
- Open
- $100.50
- Day Range
- $100.00 – $101.50
- Volume
- 3,368,992
- Prev Close
- $100.72
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 5.12% |
| Beta vs SPY | 0.66 |
| Cost of Equity (CAPM) | 8.43% (VRP-adj) |
| WACC | 7.82% |
| Volatility Risk Premium | +41.9pp (IV − HV30) |
| Effective Tax Rate | 20.2% |
| Rev. Growth (YoY, DCF input) | +8.9% |
| DCF Horizon | 10 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.09 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $6.1B |
| Return on Equity (TTM) | 10.4% |
| Book / Price | 39.3% — banking bias active (P/B is primary) |
| Gross Margin (TTM) | 65.0% |
| FCF Margin (TTM) | 16.3% |
| Debt / Equity | 0.50 |
| Quality Score | 3/6 — normal (10y DCF) |
| Market-Implied Growth | +6.8% (reverse-DCF on current price) |
| SMA 50 | $94.27 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $99.73 |
| Bollinger Width / SMA20 | 13.7% (drives anchor stability) |
| Net Debt | $23.9B |
| Market Cap | $129B |
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | $116.75 | 18% | |
| DDM (Gordon) | $87.67 | 14% | |
| Peer P/E | $100.74 | 5% | median 22.7× · 6 peers |
| Peer EV/EBITDA | $114.44 | 5% | median 15.6× · 6 peers |
| Peer P/B | $121.28 | 5% | median 3.1× · 6 peers |
| Peer P/S | $90.96 | 5% | median 2.9× · 6 peers |
| Market Anchor (SMA50) | $94.27 | 29% | stability 82% (BB-width) |
| Options Expected (B-L 30d) | $114.90 | 18% | 30 strikes · skew +0.13 |
- Industry (SIC)
- ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS (3845) · industry map
- Exchange
- XNYS
- Market Cap
- $128.8B
- Employees
- 95,000
- List Date
- 1972-06-01
- CIK
- 0001613103
- Next Earnings
- 2026-11-24 (Pre-Market)
- EPS Forecast
- $1.33
- Headquarters
- Galway
- Homepage
- https://www.medtronic.com
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, surgical robots, spinal fixation devices, neurovascular products, advanced energy, ablation laser therapy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -4.04% | -2.46% | 6.94% | 5.67% | 13.21% | 7.19% | 4.42% |
| Feb | 5.21% | 1.35% | -3.46% | -5.37% | 1.65% | -4.92% | -0.92% |
| Mar | 0.23% | 7.03% | -1.78% | 4.25% | -4.71% | -11.67% | -1.11% |
| Apr | 10.77% | -7.25% | 14.16% | -7.79% | -4.22% | -5.91% | -0.04% |
| May | -3.51% | -2.90% | -8.73% | 0.59% | -0.69% | -7.74% | -3.83% |
| Jun | -0.53% | -8.21% | 6.47% | -4.15% | 4.10% | 5.74% | 0.57% |
| Jul | 4.11% | 1.25% | 0.71% | 4.15% | 1.68% | 7.73% | 3.27% |
| Aug | 1.69% | -5.54% | -7.05% | 10.05% | 3.88% | 4.58% | 1.27% |
| Sep | -6.57% | -8.79% | -4.59% | 1.20% | 2.05% | -6.25% | -3.82% |
| Oct | -5.85% | 5.61% | -9.27% | -0.83% | -4.33% | 11.68% | -0.50% |
| Nov | -11.25% | -9.92% | 11.88% | -3.92% | 16.77% | 1.01%* | 0.76% |
| Dec | -1.92% | -1.93% | 2.99% | -7.70% | -7.04% | -- | -3.12% |
| Total | -12.79% | -28.81% | 5.03% | -5.46% | 21.55% | -1.54% | -3.67% |
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
Momentum Oscillators
Volume & Volatility
Data Summary
LLM Stock Analysis Report
Executive Summary Overall assessment: NEUTRAL with confidence level (5/10) Key drivers and primary risks: * Recent news headlines suggest positive sentiment, but IV rank suggests low volatility * Beta indicates low risk relative to market * Technical indicators indicate a range-bound trend with no clear direction
Investment thesis: MDT is likely to consolidate in the near term due to recent neutral news headlines and low volatility. However, the options market expects a move by expiration, which could be driven by upcoming earnings or regulatory changes.
Recent news sentiment impact: The positive sentiment from recent news headlines (2-5) may support the stock price in the short term, but the neutral overall assessment suggests that the market is not overly excited about the company's prospects.
Technical Analysis Trend Direction: Short-term (1-4 weeks): NEUTRAL Medium-term (1-3 months): NEUTRAL Long-term (3-12 months): BULLISH
Support/Resistance Levels: * SMA 20: $84.23 (support) * SMA 50: $81.68 (support) * Upper Bollinger Band: $88.75 (resistance)
Momentum Signals: * RSI (14): 61.92 (neutral) * MACD: Bullish, with a signal line crossover above the zero line * Bollinger Bands: Neutral, with no clear directional signal
Volume Analysis: * Volume SMA 20: 7082797.95 (low volume) * On-Balance Volume (OBV): 58790186.81 (neutral) * Volume Rate of Change: 12.96% (positive)
News & Sentiment Analysis Recent Headlines Summary: The news headlines suggest a mix of positive and neutral sentiment, with no clear direction or significant market-moving events.
Sentiment Assessment: Aggregate news sentiment is NEUTRAL, with some positive and negative themes.
Catalyst Identification: No specific catalysts identified, but upcoming earnings and regulatory changes could impact the stock price.
Market Narrative: The recent news headlines are generally neutral, which may support the current range-bound trend. The market is not overly excited about MDT's prospects, which suggests a lack of significant buying or selling pressure.
Risk & Volatility Assessment Beta Interpretation: Low risk relative to market (beta 0.20)
Volatility Regime: Low volatility (historical volatility HV20-30%)
Options Market Signals: IV rank is low at 22.8%, indicating historically low volatility. Put/call ratios are bearish, with a put/call volume ratio of 2.10 and an open interest ratio of 0.27.
Downside Protection: Support levels include SMA 20 ($84.23) and SMA 50 ($81.68). Risk management considerations include stop-loss levels around $83.16 (1% below current price) and position sizing based on the stock's volatility.
Market Context & Positioning Sector Performance: Medical devices sector is performing relatively well, with some stocks experiencing significant gains.
Institutional Activity: Low institutional interest, as reflected in the options market activity.
Correlation Analysis: MDT is positively correlated with the medical devices sector (R-squared 0.11).
Relative Valuation: MDT is trading within its historical range, with no clear directional signal or relative strength vs the broader market.
Key Levels & Action Items Critical Price Levels: * Support: SMA 20 ($84.23) * Resistance: Upper Bollinger Band ($88.75)
Breakout/Breakdown Levels: No specific levels identified, but a breakout above $90 could signal bullish momentum.
Time-Sensitive Catalysts: Upcoming earnings and regulatory changes may impact the stock price.
Risk Management: Stop-loss levels around $83.16 (1% below current price) and position sizing based on the stock's volatility.
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-02-23 | Pre-Market | 3.88% | 1.94% | 0.50x | Within |
| 2021-05-27 | Pre-Market | 2.67% | 0.89% | 0.33x | Within |
| 2021-08-24 | Pre-Market | 3.44% | 3.18% | 0.92x | Within |
| 2021-11-23 | Pre-Market | 3.51% | 3.00% | 0.85x | Within |
| 2022-05-26 | Pre-Market | 3.81% | 5.78% | 1.52x | Exceeded |
| 2022-08-23 | Pre-Market | 3.74% | 3.08% | 0.82x | Within |
| 2022-11-22 | Pre-Market | 3.80% | 5.30% | 1.39x | Exceeded |
| 2023-05-25 | Pre-Market | 3.42% | 4.51% | 1.32x | Exceeded |
| 2023-08-22 | Pre-Market | 4.15% | 2.59% | 0.62x | Within |
| 2023-11-21 | Pre-Market | 3.27% | 4.60% | 1.41x | Exceeded |
| 2024-05-23 | Pre-Market | 4.15% | 5.11% | 1.23x | Exceeded |
| 2024-08-20 | Pre-Market | 3.99% | 0.66% | 0.17x | Within |
| 2024-11-19 | Pre-Market | 3.78% | 2.96% | 0.78x | Within |
| 2025-02-18 | After-Close | 2.08% | 0.81% | 0.39x | Within |
| 2025-05-21 | Pre-Market | 4.60% | 2.27% | 0.49x | Within |
| 2025-08-19 | Pre-Market | 5.52% | 3.14% | 0.57x | Within |
| 2025-11-18 | Pre-Market | 3.87% | 4.69% | 1.21x | Exceeded |
| 2026-02-17 | Pre-Market | 5.04% | 2.83% | 0.56x | Within |
| 2026-06-03 | Pre-Market | 5.09% | 5.69% | 1.12x | Exceeded |
| 2026-09-01 | Pre-Market | 5.53% | 1.53% | 0.28x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
MDT Options Activity & IV Rank
MDT IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Options Flow · All expiries
ATM Options Pricing
Chain Summary
MDT Implied Volatility
Loading implied volatility…
The 30-day IV is the at-the-money implied volatility of options 30 days out, the blue line. The band is its 20-session average, 2 standard deviations either side. Realized volatility is how much MDT actually moved over the last 20 sessions, from closing prices, on the same yearly scale. Without earnings takes each earnings report out of the 30-day IV, sized from what options paid for past reports, so it shows whether options are expensive or cheap apart from the report. Click a name above the chart to show or hide it.
Each spread is ranked by a composite score built in three stages. Full documentation →
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Estimated net dealer gamma is at the 77th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
IV(call wing) − IV(ATM), in vol pointsThe same measure on the upside: how the OTM call is priced against the at-the-money strike.
- Negative (typical) — calls trade below ATM for most stocks and indices, so the sign alone says little.
- Percentile vs own history: high = upside calls unusually rich for this name (squeezes, takeover talk, commodity supply scares); low = calls cheaper than usual.
Put or call vs ATM tells you how expensive that tail is. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Loading the implied volatility surface…
Loading the implied volatility smile…
Risk Metrics
Analysis Details
Data Points: 251
Period: 252 trading days
Low volatility - stock moves less than market
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Citadel Hedge fund Ken Griffin | $420.4M | #59 of 6285 | +446.8% | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $76.6M | #210 of 3151 | -72.0% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $74.1M | #169 of 4858 | +3.3% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $71.9M | #462 of 3716 | +94.5% | 13F | |
| Bridgewater Associates Hedge fund Ray Dalio | $37.7M | #108 of 997 | +89.0% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
MDT Institutional Ownership (13F)
Filings for 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Barclays PLC Custodian | $536.15M | 33.21% | 2026-09-30 |
| 2 | Jane Street Group, LLC Custodian | $253.07M | 15.68% | 2026-09-30 |
| 3 | Susquehanna International Group, LLP Custodian | $203.96M | 12.63% | 2026-06-30 |
| 4 | NOMURA HOLDINGS INC | $98.72M | 6.12% | 2026-06-30 |
| 5 | UBS Group AG Custodian | $80.03M | 4.96% | 2026-09-30 |
| 6 | Citadel Advisors LLC Custodian | $64.99M | 4.03% | 2026-06-30 |
| 7 | ELEMENT CAPITAL MANAGEMENT LLC | $61.84M | 3.83% | 2026-09-30 |
| 8 | IMC-Chicago, LLC Custodian | $59.03M | 3.66% | 2026-09-30 |
| 9 | Walleye Capital LLC Custodian | $57.42M | 3.56% | 2026-09-30 |
| 10 | Bank of Montreal Custodian | $43.15M | 2.67% | 2026-09-30 |
| 11 | Millennium Management LLC Custodian | $23.71M | 1.47% | 2026-06-30 |
| 12 | Verition Fund Management LLC | $19.26M | 1.19% | 2026-09-30 |
| 13 | GROUP ONE TRADING LLC Custodian | $18.08M | 1.12% | 2026-09-30 |
| 14 | Simplex Trading, LLC Custodian | $17.68M | 1.10% | 2026-09-30 |
| 15 | Hudson Bay Capital Management LP | $12.94M | 0.80% | 2026-09-30 |
| 16 | BNP Paribas Financial Markets Custodian | $9.96M | 0.62% | 2026-09-30 |
| 17 | Point72 Asset Management, L.P. | $7.79M | 0.48% | 2026-06-30 |
| 18 | TUDOR INVESTMENT CORP ET AL | $7.63M | 0.47% | 2026-06-30 |
| 19 | Allianz Asset Management GmbH | $6.16M | 0.38% | 2026-06-30 |
| 20 | CAPITAL FUND MANAGEMENT S.A. | $5.95M | 0.37% | 2026-09-30 |
| 21 | JPMorgan Chase & Co Custodian | $5.60M | 0.35% | 2026-09-30 |
| 22 | Caption Management, LLC | $3.91M | 0.24% | 2026-06-30 |
| 23 | Royal Bank of Canada Custodian | $3.61M | 0.22% | 2026-09-30 |
| 24 | Qube Research & Technologies Ltd | $3.25M | 0.20% | 2026-09-30 |
| 25 | Squarepoint Ops LLC | $2.37M | 0.15% | 2026-09-30 |
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Qube Research & Technologies Ltd | $390.38M | 25.13% | 2026-09-30 |
| 2 | UBS Group AG Custodian | $229.00M | 14.74% | 2026-09-30 |
| 3 | Susquehanna International Group, LLP Custodian | $157.10M | 10.11% | 2026-06-30 |
| 4 | Jane Street Group, LLC Custodian | $153.04M | 9.85% | 2026-09-30 |
| 5 | Citadel Advisors LLC Custodian | $123.56M | 7.95% | 2026-06-30 |
| 6 | SUMMIT SECURITIES GROUP LLC | $94.92M | 6.11% | 2026-09-30 |
| 7 | NOMURA HOLDINGS INC | $78.23M | 5.04% | 2026-06-30 |
| 8 | Verition Fund Management LLC | $46.48M | 2.99% | 2026-09-30 |
| 9 | Squarepoint Ops LLC | $45.54M | 2.93% | 2026-09-30 |
| 10 | Walleye Capital LLC Custodian | $39.13M | 2.52% | 2026-09-30 |
| 11 | IMC-Chicago, LLC Custodian | $30.04M | 1.93% | 2026-09-30 |
| 12 | Centiva Capital, LP | $23.22M | 1.49% | 2026-09-30 |
| 13 | Yakira Capital Management, Inc. | $21.81M | 1.40% | 2026-09-30 |
| 14 | Millennium Management LLC Custodian | $18.43M | 1.19% | 2026-06-30 |
| 15 | Caption Management, LLC | $11.34M | 0.73% | 2026-06-30 |
| 16 | Cresset Asset Management, LLC | $9.88M | 0.64% | 2026-06-30 |
| 17 | Allianz Asset Management GmbH | $9.07M | 0.58% | 2026-06-30 |
| 18 | Marathon Trading Investment Management LLC | $8.63M | 0.56% | 2026-09-30 |
| 19 | Balyasny Asset Management L.P. | $7.83M | 0.50% | 2026-06-30 |
| 20 | CAPSTONE INVESTMENT ADVISORS, LLC | $7.82M | 0.50% | 2026-06-30 |
| 21 | JPMorgan Chase & Co Custodian | $7.23M | 0.47% | 2026-09-30 |
| 22 | BNP Paribas Financial Markets Custodian | $6.05M | 0.39% | 2026-09-30 |
| 23 | CREDIT AGRICOLE S A | $4.31M | 0.28% | 2026-09-30 |
| 24 | CIBC Bancorp USA Inc. Custodian | $4.31M | 0.28% | 2026-09-30 |
| 25 | Simplex Trading, LLC Custodian | $4.29M | 0.28% | 2026-09-30 |
MDT Insider Trading (Form 4)
Latest: 2026-11-04| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-11-04 | Michael Marinaro | President | Award (A) | +6,547 | — | EDGAR | |
| 2026-10-21 | Kevin E Lofton | Director | Other (J) | −182 | — | EDGAR | |
| 2026-10-16 | Geoffrey Martha | Chairman and CEO | Sell (S) | −50,000 | $95.00 | -$4.75M | EDGAR |
| 2026-10-16 | Michael Marinaro | EVP, Pres MedSurg and Americas | Sell (S) | −10,420 | $96.00 | -$1.00M | EDGAR |
| 2026-09-17 | Harry Skip Kiil | EVP & President Cardiovascular | Sell (S) | −1,483 | $93.65 | -$138.9K | EDGAR |
| 2026-09-16 | Denise L. Blomquist | Chief Accounting Officer | Gift (G) | −600 | — | EDGAR | |
| 2026-08-24 | Michael Marinaro | EVP, Pres MedSurg and Americas | Tax (F) | −1,084 | $92.30 | -$100.1K | EDGAR |
| 2026-08-04 | Thierry Pieton | EVP & Chief Financial Officer | Award (A) | +11,537 | — | EDGAR | |
| 2026-08-04 | Denise L. Blomquist | Chief Accounting Officer | Mixed Tax −212 · Grant +2,337 |
+2,125 | $85.39 | -$18.1K | EDGAR |
| 2026-08-04 | Kweli Thompson | EVP & President, Neuroscience | Mixed Tax −1,739 · Grant +6,923 |
+5,184 | $85.39 | -$148.5K | EDGAR |
| 2026-08-04 | Geoffrey Martha | Chairman and CEO | Mixed Grant +41,533 · Tax −15,810 |
+25,723 | $85.39 | -$1.35M | EDGAR |
| 2026-08-04 | Harry Skip Kiil | EVP & President Cardiovascular | Mixed Grant +9,230 · Tax −3,074 |
+6,156 | $85.39 | -$262.5K | EDGAR |
| 2026-08-04 | Michelle Quinn | EVP, GC and Secretary | Award (A) | +6,346 | — | EDGAR | |
| 2026-08-04 | Michael Marinaro | EVP, Pres MedSurg and Americas | Mixed Grant +57,107 · Tax −3,356 |
+53,751 | $85.39 | -$286.6K | EDGAR |
| 2026-08-04 | Matthew R. Walter | SVP, Chief HR Officer | Mixed Grant +5,769 · Tax −1,675 |
+4,094 | $85.39 | -$143.0K | EDGAR |
MDT Insider Holdings
26 insiders · @ $100.48| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Geoffrey Martha | Chairman and CEO | 277,866 | $27.92M | -$16.99M | 44 | 2026-10-16 |
| 2 | Michael Marinaro | President | 113,353 | $11.39M | -$1.19M | 19 | 2026-11-04 |
| 3 | Randall J Hogan | Director | 86,082 | $8.65M | $0 | 23 | 2026-04-29 |
| 4 | Brett A. Wall | EVP & Pres Neuroscience | 82,183 | $8.26M | -$2.91M | 26 | 2026-05-28 |
| 5 | Sean Salmon | EVP & President Cardiovascular | 64,722 | $6.50M | -$7.76M | 20 | 2024-12-17 |
| 6 | Ivan K Fong | EVP GENERAL COUNSEL & SECR | 54,692 | $5.50M | $0 | 9 | 2024-12-17 |
| 7 | Kendall J Powell | Director | 54,380 | $5.46M | -$599.6K | 31 | 2026-04-29 |
| 8 | Thierry Pieton | EVP & Chief Financial Officer | 49,645 | $4.99M | $0 | 5 | 2026-08-04 |
| 9 | Gregory L Smith | EVP Global Ops & Supply Chain | 46,016 | $4.62M | -$3.90M | 13 | 2025-11-21 |
| 10 | Gary Louis Corona | Interim CFO | 44,255 | $4.45M | $0 | 3 | 2025-01-23 |
MDT Board & Officers
As of SEC filings through Nov 4, 2026Directors 12
- Elizabeth G Nabel · since Sep 16, 2014
- Craig Arnold · on file since Jan 2015
- Randall J Hogan · on file since Jan 2015
- Kendall J Powell · listed since Feb 2015
- Scott C Donnelly · listed since Feb 2015
- Geoffrey Martha · listed since Aug 2020
- Kevin E Lofton · since Sep 15, 2020
- Lidia Fonseca · since Jun 27, 2022
- Gregory P Lewis · since Jun 26, 2023
- Joon Sup Lee · since Jun 18, 2025
- John P Groetelaars · since Aug 19, 2025
- William R Jellison · since Aug 19, 2025
Officers 9
- Geoffrey Martha · Chairman and CEO · listed since Aug 2022
- Harry Skip Kiil · EVP & President Cardiovascular · since May 21, 2025
- Kweli Thompson · EVP & President, Neuroscience · since Jun 18, 2026
- Thierry Pieton · EVP & Chief Financial Officer · since Mar 3, 2025
- Matthew R. Walter · SVP, Chief HR Officer · since Jun 24, 2024
- Denise L. Blomquist · Chief Accounting Officer · since Mar 17, 2025
- Michelle Quinn · EVP, GC and Secretary · since Jul 21, 2025
- Brett A. Wall · EVP & Pres Neuroscience · listed since Jun 2021
- Michael Marinaro · EVP, Pres MedSurg and Americas · listed since Jul 2025
Changes in the last 10 years (39)
| Jun 18, 2026 | Kweli Thompson became EVP & President, Neuroscience |
| Nov 1, 2025 | The company announced the departure of Gregory L Smith as EVP Global Ops & Supply Chain in an SEC filing |
| Aug 19, 2025 | William R Jellison became a director |
| Aug 19, 2025 | John P Groetelaars became a director |
| Jul 30, 2025 | Michael Marinaro listed as EVP, Pres MedSurg and Americas (previously EVP & President, Surgical OU) in SEC filings |
| Jul 21, 2025 | Michelle Quinn became EVP, GC and Secretary |
| Jun 18, 2025 | Joon Sup Lee became a director |
| May 21, 2025 | The company announced the departure of Sean Salmon as EVP & President Cardiovascular in an SEC filing |
| May 21, 2025 | Harry Skip Kiil became EVP & President Cardiovascular |
| Mar 17, 2025 | Denise L. Blomquist became Chief Accounting Officer |
| Mar 3, 2025 | Thierry Pieton became EVP & Chief Financial Officer |
| Aug 6, 2024 | Karen L Parkhill reported in an SEC filing no longer being EVP & Chief Financial Officer |
| Aug 3, 2024 | Gary Louis Corona became Interim CFO |
| Jun 24, 2024 | Matthew R. Walter became SVP, Chief HR Officer |
| Jun 26, 2023 | Michael Marinaro became EVP & President, Surgical OU |
| Jun 26, 2023 | Gregory P Lewis became a director |
| Oct 17, 2022 | Rob Ten Hoedt listed as EVP and Pres. Global Regions (previously EVP & President EMEA) in SEC filings |
| Aug 2, 2022 | Sean Salmon listed as EVP & President Cardiovascular (previously EVP & Pres Diabetes/Cardiovasc) in SEC filings |
| Aug 2, 2022 | Geoffrey Martha listed as Chairman and CEO (previously CEO) in SEC filings |
| Aug 2, 2022 | Carol A Surface listed as EVP, Chief HR Officer (previously SVP, Chief HR Officer) in SEC filings |
| Jun 27, 2022 | Lidia Fonseca became a director |
| Jun 27, 2022 | Gregory L Smith became EVP Global Ops & Supply Chain |
| Feb 1, 2022 | Ivan K Fong became EVP General Counsel & Secr |
| Dec 14, 2021 | The company announced the departure of Richard Kuntz as SVP & Chief Medical & Science in an SEC filing |
| Aug 4, 2021 | Sean Salmon listed as EVP & Pres Diabetes/Cardiovasc (previously EVP & Group President Diabetes) in SEC filings |
| Jun 30, 2021 | Jennifer M Kirk became Chief Accounting Officer |
| Jun 2, 2021 | Brett A. Wall listed as EVP & Pres Neuroscience (previously EVP & Group Pres Restora Thera) in SEC filings |
| Dec 21, 2020 | Robert John White listed as EVP & Pres. Medical Surgical (previously EVP & President MITG) in SEC filings |
| Sep 15, 2020 | Kevin E Lofton became a director |
| Aug 3, 2020 | Geoffrey Martha listed as CEO (previously EVP & GroupPres Restora Therap) in SEC filings |
| Aug 3, 2020 | Geoffrey Martha first listed as a director in an SEC filing |
| Jul 2, 2020 | Omar Ishrak listed as Executive Chairman (previously Chairman & CEO) in SEC filings |
| Nov 1, 2019 | Sean Salmon became EVP & Group President Diabetes |
| Nov 1, 2019 | Brett A. Wall became EVP & Group Pres Restora Thera |
| Mar 8, 2019 | Andrea Jo Goldsmith became a director |
| Aug 29, 2018 | John R Liddicoat became EVP & President of Americas |
| Jun 11, 2018 | Richard Kuntz listed as SVP & Chief Medical & Science (previously SrVP & Chief Scien, Clin, Reg) in SEC filings |
| Dec 19, 2017 | Robert John White became EVP & President MITG |
| Jan 4, 2017 | Gary Lee Ellis reported in an SEC filing no longer being EVP & Global Ops and IT |
- Prev
- 1
Not reported recently (19)
- Andrea Jo Goldsmith · Last reported as a director in an SEC filing dated Apr 30, 2025
- Gary Louis Corona · Last reported as Interim CFO in an SEC filing dated Jan 23, 2025
- Ivan K Fong · Last reported as EVP General Counsel & Secr in an SEC filing dated Dec 17, 2024
- Jennifer M Kirk · Last reported as Chief Accounting Officer in an SEC filing dated Dec 10, 2024
- Denise M Oleary · Last reported as a director in an SEC filing dated May 3, 2024
- Robert John White · Last reported as EVP & Pres. Medical Surgical in an SEC filing dated Dec 12, 2023
- Rob Ten Hoedt · Last reported as EVP and Pres. Global Regions in an SEC filing dated Aug 7, 2023
- Richard H Anderson · Last reported as a director in an SEC filing dated May 3, 2023
- Carol A Surface · Last reported as EVP, Chief HR Officer in an SEC filing dated Aug 3, 2022
- John R Liddicoat · Last reported as EVP & President of Americas in an SEC filing dated Aug 2, 2022
- Bradley E Lerman · Last reported as SVP General Counsel & Corp Sec in an SEC filing dated Nov 9, 2021
- James T Lenehan · Last reported as a director in an SEC filing dated May 4, 2021
- Michael O Leavitt · Last reported as a director in an SEC filing dated May 4, 2021
- Omar Ishrak · Last reported as a director in an SEC filing dated Dec 11, 2020
- Michael J Coyle · Last reported as EVP & Group Pres, Cardiac&Vasc in an SEC filing dated Nov 5, 2020
- Hooman Hakami · Last reported as EVP & Group President Diabetes in an SEC filing dated Sep 12, 2019
- Robert C Pozen · Last reported as a director in an SEC filing dated Aug 24, 2018
- Shirley A Jackson · Last reported as a director in an SEC filing dated May 2, 2018
- Bryan C Hanson · Last reported as EVP, President, MITG in an SEC filing dated Dec 18, 2017
MDT Proposed Insider Sales (Form 144)
Latest: 2026-10-15What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-10-15 | Marinaro Michael | Officer | 10,420 | $1.00M | 2026-10-15 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-10-15 | Martha Geoffrey | Officer, Director | 50,000 | $4.75M | 2026-10-15 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-09-16 | KIIL HARRY SKIP | Officer | 1,483 | $138.9K | 2026-09-16 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-07-08 | Walter Matthew R. | Officer | 3,102 | $257.9K | 2026-07-08 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-06-08 | KIIL HARRY SKIP | Officer | 4,189 | $337.0K | 2026-06-08 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-02-19 | KIIL HARRY SKIP | Officer | 52,524 | $5.13M | 2026-02-19 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2025-11-19 | Smith Gregory L | Officer | 30,000 | $3.06M | 2025-11-19 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2025-09-03 | KIIL HARRY SKIP | Officer | 8,605 | $788.0K | 2025-09-03 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2025-06-06 | Salmon Sean | Officer | 18,378 | $1.60M | 2025-06-06 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2025-01-24 | Wall Brett A. | Officer | 12,437 | $1.12M | 2025-01-24 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| Filing Date | Event | Link |
|---|---|---|
| 2026-10-19 | Director or officer change · Shareholder vote results · Regulation FD disclosure | EDGAR |
| 2026-09-17 | Other events | EDGAR |
| 2026-09-01 | Earnings results | EDGAR |
| 2026-06-03 | Earnings results | EDGAR |
| 2026-05-18 | Director or officer change | EDGAR |
| 2026-04-27 | Regulation FD disclosure | EDGAR |
| 2026-03-24 | Regulation FD disclosure | EDGAR |
| 2026-02-17 | Earnings results | EDGAR |
| 2025-11-18 | Earnings results | EDGAR |
| 2025-11-03 | Director or officer change | EDGAR |
| Filing Date | Accession | Link |
|---|---|---|
| 2026-06-18 | 0001628280-26-044354 | EDGAR |
| 2025-06-20 | 0001613103-25-000091 | EDGAR |
| 2024-06-20 | 0001613103-24-000072 | EDGAR |
| 2023-06-22 | 0001613103-23-000040 | EDGAR |
| 2022-06-23 | 0001613103-22-000023 | EDGAR |
| 2021-06-25 | 0001613103-21-000027 | EDGAR |
| 2020-06-19 | 0001613103-20-000021 | EDGAR |
| 2019-06-21 | 0001613103-19-000028 | EDGAR |
| 2018-06-22 | 0001613103-18-000024 | EDGAR |
| 2017-06-27 | 0001613103-17-000018 | EDGAR |
| Filing Date | Accession | Link |
|---|---|---|
| 2026-09-03 | 0001628280-26-060473 | EDGAR |
| 2026-02-24 | 0001628280-26-011107 | EDGAR |
| 2025-11-25 | 0001628280-25-053988 | EDGAR |
| 2025-08-26 | 0001613103-25-000161 | EDGAR |
| 2025-02-25 | 0001613103-25-000022 | EDGAR |
| 2024-11-26 | 0001613103-24-000165 | EDGAR |
| 2024-08-27 | 0001613103-24-000147 | EDGAR |
| 2024-02-27 | 0001613103-24-000011 | EDGAR |
| 2023-11-30 | 0001613103-23-000149 | EDGAR |
| 2023-08-31 | 0001613103-23-000128 | EDGAR |
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VOO Vanguard S&P 500 ETF | Vanguard | 0.18% | $3.1B | — | 2026-10-31 |
| 2 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.16% | $3.0B | — | 2026-10-31 |
| 3 | IVV iShares Core S&P 500 ETF | iShares (BlackRock) | 0.20% | $1.7B | $850.5B | 2026-11-17 |
| 4 | SPY State Street® SPDR® S&P 500® ETF Trust | SPDR (State Street) | 0.20% | $1.5B | $783.9B | 2026-11-17 |
| 5 | VTV Vanguard Morningstar Value ETF | Vanguard | 0.43% | $1.1B | — | 2026-10-31 |
| 6 | XLV State Street® Health Care Select Sector SPDR® ETF | SPDR (State Street) | 1.87% | $924.6M | $49.6B | 2026-11-17 |
| 7 | VIG Vanguard Dividend Appreciation ETF | Vanguard | 0.49% | $670.6M | — | 2026-10-31 |
| 8 | CGDV Capital Group Dividend Value ETF | Capitalgroup | 1.30% | $509.8M | $39.1B | 2026-11-17 |
| 9 | VYM Vanguard High Dividend Yield ETF | Vanguard | 0.48% | $482.4M | — | 2026-10-31 |
| 10 | IHI iShares U.S. Medical Devices ETF | iShares (BlackRock) | 11.77% | $469.3M | $4.0B | 2026-11-17 |
| 11 | DGRO iShares Core Dividend Growth ETF | iShares (BlackRock) | 0.88% | $396.9M | $44.7B | 2026-11-17 |
| 12 | VHT Vanguard Health Care ETF | Vanguard | 1.60% | $379.5M | — | 2026-10-31 |
| 13 | SDY State Street® SPDR® S&P® Dividend ETF | SPDR (State Street) | 1.60% | $358.5M | $22.4B | 2026-11-17 |
| 14 | SPYM State Street® SPDR® Portfolio S&P 500® ETF | SPDR (State Street) | 0.20% | $356.9M | $180.6B | 2026-11-17 |
| 15 | HDV iShares Core High Dividend ETF | iShares (BlackRock) | 1.99% | $328.2M | $16.3B | 2026-11-17 |
| 16 | DYNF iShares U.S. Equity Factor Rotation Active ETF | iShares (BlackRock) | 0.73% | $301.0M | $40.9B | 2026-11-17 |
| 17 | IWD iShares Russell 1000 Value ETF | iShares (BlackRock) | 0.33% | $277.2M | $82.5B | 2026-11-17 |
| 18 | RSP Invesco S&P 500 Equal Weight ETF | Invesco | 0.22% | $227.9M | — | 2026-11-17 |
| 19 | FDL First Trust Morningstar Dividend Leaders Index Fund | First Trust | 2.53% | $213.4M | $8.4B | 2026-11-17 |
| 20 | JEPI JPMorgan Equity Premium Income ETF | JPMorgan | 0.46% | $213.3M | $46.0B | 2026-11-18 |
| 21 | IVE iShares S&P 500 Value ETF | iShares (BlackRock) | 0.42% | $205.3M | $49.1B | 2026-11-17 |
| 22 | NOBL ProShares S&P 500 Dividend Aristocrats ETF | ProShares | 1.53% | $184.9M | — | 2026-11-18 |
| 23 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.18% | $166.7M | $93.0B | 2026-11-17 |
| 24 | SPYV State Street® SPDR® Portfolio S&P 500® Value ETF | SPDR (State Street) | 0.42% | $158.5M | $38.1B | 2026-11-17 |
| 25 | VV Vanguard Morningstar Large-Cap ETF | Vanguard | 0.19% | $139.0M | — | 2026-10-31 |
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q1 '27 | 2026-07-31 | $9.76B | $1.47B | $1.14 | $1.79B |
| Q4 '26 | 2026-04-24 | $9.81B | $1.24B | $0.97 | $2.57B |
| Q3 '26 | 2026-01-23 | $9.02B | $1.14B | $0.89 | $2.74B |
| Q2 '26 | 2025-10-24 | $8.96B | $1.37B | $1.07 | $925.00M |
| Q1 '26 | 2025-07-25 | $8.58B | $1.04B | $0.81 | $1.09B |
| Q4 '25 | 2025-04-25 | $8.93B | $1.06B | $0.82 | $2.53B |
| Q3 '25 | 2025-01-24 | $8.29B | $1.29B | $1.01 | $2.57B |
| Q2 '25 | 2024-10-25 | $8.40B | $1.27B | $0.99 | $958.00M |
| Q1 '25 | 2024-07-26 | $7.92B | $1.04B | $0.80 | $986.00M |
| Q4 '24 | 2024-04-26 | $8.59B | $654.00M | $0.49 | $2.78B |
| Q3 '24 | 2024-01-26 | $8.09B | $1.32B | $0.99 | $2.47B |
| Q2 '24 | 2023-10-27 | $7.98B | $909.00M | $0.68 | $661.00M |
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
MDT vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| LLY Eli Lilly & Co. | $1.23T | 44.0 | +45.5% | +25.6% | 35 |
| JNJ Johnson & Johnson | $656.5B | 40.4 | +7.8% | +28.4% | 87 |
| ABBV ABBVIE INC. | $505.6B | 48.7 | +10.7% | +23.4% | 50 |
| MRK Merck & Co., Inc. | $339.7B | 136.1 | +4.9% | +24.0% | 62 |
| ABT Abbott Laboratories | $181.0B | 38.5 | +10.0% | −16.2% | 30 |
| ISRG Intuitive Surgical Inc. | $145.9B | 49.3 | +20.5% | −27.4% | 30 |
| MDT Medtronic plc | $128.8B | 24.7 | +9.8% | +4.6% | 65 |
| BMY Bristol-Myers Squibb Co. | $121.7B | 12.9 | +3.1% | +9.2% | 86 |
| BDX Becton, Dickinson and Co. | $58.9B | 64.2 | +1.2% | +9.0% | 29 |
| Peer median | $260.3B | 46.4 | +8.9% | +16.3% | 42 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.